Protalix Historical Income Statement
| PLX Stock | USD 1.13 0.02 1.74% |
Historical analysis of Protalix Biotherapeutics income statement accounts such as EBITDA of 12.2 M, Total Operating Expenses of 25 M, Income Before Tax of 9 M or Net Income of 8.7 M can show how well Protalix Biotherapeutics performed in making a profits. Evaluating Protalix Biotherapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Protalix Biotherapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Protalix Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protalix Biotherapeutics is a good buy for the upcoming year.
Protalix |
About Protalix Income Statement Analysis
Protalix Biotherapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Protalix Biotherapeutics shareholders. The income statement also shows Protalix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Protalix Biotherapeutics Income Statement Chart
Protalix Biotherapeutics Income Statement is one of the three primary financial statements used for reporting Protalix's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Protalix Biotherapeutics revenue and expense. Protalix Biotherapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Protalix Biotherapeutics' Research Development is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 8.7 M in 2024, whereas Interest Expense is likely to drop slightly above 2.8 M in 2024. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Protalix Biotherapeutics. It is also known as Protalix Biotherapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Total Revenue
Total revenue comprises all receipts Protalix Biotherapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Protalix Biotherapeutics minus its cost of goods sold. It is profit before Protalix Biotherapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Protalix Biotherapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Research Development is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 8.7 M in 2024, whereas Interest Expense is likely to drop slightly above 2.8 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 38.4M | 47.6M | 65.5M | 68.8M | Depreciation And Amortization | 401K | 2.2M | 1.2M | 1.7M |
Protalix Biotherapeutics income statement Correlations
Click cells to compare fundamentals
Protalix Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protalix Biotherapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 8.0M | 9.7M | 7.5M | 2.5M | 3.2M | 2.8M | |
| Selling General Administrative | 6.0M | (5.1M) | (4.0M) | (13.6M) | (25.5M) | (24.2M) | |
| Other Operating Expenses | 65.4M | 60.2M | 58.8M | 60.7M | 55.0M | 31.5M | |
| Operating Income | (10.7M) | 1.8M | (20.5M) | (13.0M) | 10.5M | 11.0M | |
| Ebit | (10.7M) | 1.8M | (20.5M) | (13.0M) | 10.5M | 11.0M | |
| Ebitda | (8.7M) | 3.1M | (20.1M) | (10.8M) | 11.7M | 12.2M | |
| Total Operating Expenses | 54.5M | 49.3M | 42.5M | 41.1M | 32.1M | 25.0M | |
| Income Before Tax | (18.3M) | (6.5M) | (27.6M) | (14.4M) | 8.6M | 9.0M | |
| Total Other Income Expense Net | (7.6M) | (8.4M) | (7.1M) | (1.4M) | (1.9M) | (1.8M) | |
| Net Income | (26.2M) | (14.9M) | (34.0M) | (14.9M) | 8.3M | 8.7M | |
| Income Tax Expense | 8.0M | 8.4M | 6.4M | 530K | 254K | 241.3K | |
| Depreciation And Amortization | 2.0M | 1.3M | 401K | 2.2M | 1.2M | 1.7M | |
| Total Revenue | 54.7M | 62.9M | 38.4M | 47.6M | 65.5M | 68.8M | |
| Gross Profit | 43.8M | 52.0M | 22.0M | 28.0M | 42.5M | 44.6M | |
| Cost Of Revenue | 10.9M | 10.9M | 16.3M | 19.6M | 23.0M | 24.1M | |
| Selling And Marketing Expenses | 15.9M | 16.2M | 16.7M | 25.3M | 40.4M | 42.4M | |
| Research Development | 44.6M | 38.2M | 29.7M | 29.3M | 17.1M | 28.1M | |
| Net Income From Continuing Ops | (18.3M) | (6.5M) | (27.6M) | (14.9M) | 8.3M | 8.7M | |
| Net Income Applicable To Common Shares | (18.3M) | (6.5M) | (27.6M) | (14.9M) | (13.4M) | (14.1M) | |
| Net Interest Income | (7.6M) | (9.2M) | (7.1M) | (1.4M) | (1.9M) | (2.0M) | |
| Interest Income | 407K | 438K | 401K | 1.1M | 1.3M | 686.3K | |
| Reconciled Depreciation | 1.6M | 1.3M | 1.1M | 1.1M | 1.2M | 1.1M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protalix Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protalix Biotherapeutics' short interest history, or implied volatility extrapolated from Protalix Biotherapeutics options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.